Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Acute Agitation and Dexmedetomidine: A Novel Treatment Approach

Acute Agitation and Dexmedetomidine: A Novel Treatment Approach

FromPsychopharmacology and Psychiatry Updates


Acute Agitation and Dexmedetomidine: A Novel Treatment Approach

FromPsychopharmacology and Psychiatry Updates

ratings:
Length:
8 minutes
Released:
Aug 30, 2023
Format:
Podcast episode

Description

In this episode, we delve into a new horizon in the management of acute agitation. We discuss dexmedetomidine, a drug that's been around since 1999, recently reformulated into a sublingual film and FDA approved for treating agitation associated with schizophrenia or bipolar I or II disorder. We explore the results from a recent randomized trial and its potential for transforming psychiatric care. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 47 Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial
Released:
Aug 30, 2023
Format:
Podcast episode

Titles in the series (100)

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.